18 results
8-K
EX-99.1
ACLX
Arcellx Inc
9 May 24
Arcellx Provides First Quarter 2024 Financial Results
4:10pm
and collaboration agreement and amendment with Kite Pharma, Inc. (Kite).
R&D expenses:
Research and development expenses were $32.3 million and $32.9 million
8-K
EX-99.1
ACLX
Arcellx Inc
28 Feb 24
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
4:02pm
performed under the arrangement described in the recent license and collaboration agreement with Kite Pharma, Inc. (Kite).
R&D expenses:
Research
8-K
EX-99.1
ACLX
Arcellx Inc
13 Nov 23
Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights
4:05pm
license and collaboration agreement with Kite Pharma, Inc. (Kite).
R&D expenses:
Research and development expenses were $43.8 million and $83.5
8-K
EX-99.1
1znmjd
14 Aug 23
Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results
4:06pm
8-K
EX-99.1
vw1wf
8 May 23
Arcellx Provides First Quarter Financial Results
4:02pm
8-K
EX-99.1
y0v51m cwqcdju
29 Mar 23
Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
4:11pm
8-K
EX-99.1
dt76rvbm15x1m 07k
9 Dec 22
Entry into a Material Definitive Agreement
8:24am
8-K
EX-99.1
amramw2 zw7alewwths
14 Nov 22
Arcellx Reports Third Quarter 2022 Financial Results and Business Progress
4:05pm
8-K
EX-99.1
ygobnqu8p4jjh4
15 Aug 22
Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results
4:15pm
8-K
EX-99.1
6s6j ngfa444gwxh5
12 May 22
Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results
4:14pm
8-K
EX-99.1
z1hbkseo 30duu7
24 Mar 22
Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
4:12pm
DRS/A
kwx7zdbu7bahw9 5s
9 Jun 20
Draft registration statement (amended)
12:00am
DRS
pf3gr542ijw
1 May 20
Draft registration statement
12:00am
- Prev
- 1
- Next